RNA-targeting Therapy: A Promising Approach to Reach Non-Druggable Targets
Dalia Zaafar1
, Toka Elemary2, Yara Abdel Hady2 and Aya Essawy31Department of Pharmacology and Toxicology, Faculty of Pharmacy, MTI University, Cairo, Egypt.
2Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
3Department of Clinical Pharmacy, Faculty of pharmacy, MTI University, Cairo, Egypt.
Corresponding Author E-mail: dalia.zaffar@pharm.mti.edu.eg
Abstract: The term "non-druggable" refers to a protein that cannot be targeted pharmacologically; recently, significant efforts have been made to convert these proteins into targets that are reachable or "druggable." Pharmacologically targeting these difficult proteins has emerged as a major challenge in modern drug development, necessitating the innovation and development of new technologies. The idea of using RNA-targeting therapeutics as a platform to reach unreachable targets is very appealing. Antisense oligonucleotides, nucleic acid or aptamers, RNA interference therapeutics, microRNA, and synthetic RNA are examples of RNA-targeting therapeutics. Many of these agents were FDA-approved for the treatment of rare or genetic diseases, as well as molecular markers for disease diagnosis. As a promising type of therapeutic, many studies are being conducted in order for more and more of them to be approved and used in different disease treatments and to shift them from treating rare diseases only to being used as more specific targeting agents in the treatment of various common diseases. This article will look at some of the most recent technological and pharmaceutical advances that have contributed to the erosion of the concept of undruggability.
Keywords: Antisense Oligonucleotides; Aptamers; Interference Therapeutics; Microrna; Synthetic RNA Back to TOC